InicioCarterasWatchlistComunidadDescubreScreener
NOT FOR DISTRIBUTION
Loading...
  • Acciones
  • /
  • Sanidad
Actualizado hace 1m
VIMIAN logo

Vimian Group AB (publ)Informe acción OM:VIMIAN

Capitalización bursátil SEK 18.3b
Actualizado hace 1m
Precio de las acciones
n/a
1Y16.2%
7D3.7%
1D2.6%
Valor de la cartera
​
Ver

Vimian Group AB (publ)

Informe acción OM:VIMIAN

Capitalización de mercado: SEK 18.3b

  • Resumen empresa
    • Valoración
    • Crecimiento Futuro
    • Rendimiento pasado
    • Salud Financiera
    • Dividendos
  • Dirección
  • Propiedad
  • Información adicional
  • Comunidad de acciones

Vimian Group (VIMIAN) Resumen de Acciones

Vimian Group AB (publ) se dedica al negocio de la salud animal en todo el mundo. Saber más

Análisis fundamental de VIMIAN
Puntuación del snowflake
Valoración3/6
Crecimiento futuro4/6
Rendimiento pasado5/6
Salud financiera4/6
Dividendos0/6

Recompensas

Cotiza un 29.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 30.06%

Los beneficios aumentaron un 61.4% el pasado año

Análisis de riesgos

No se han detectado riesgos en VIMIAN a partir de nuestros controles de riesgos.

VIMIAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
4.6% infravalorado descuento intrínseco
AnalystConsensusTarget
•2d ago

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

102
0
2
AN
AnalystHighTarget
13.6% infravalorado descuento intrínseco
AnalystHighTarget
•3mo ago

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

30
0
0
AN
AnalystLowTarget
21.9% sobrevalorado descuento intrínseco
AnalystLowTarget
•1mo ago

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

24
0
0

Top Analyst Narratives

AN
AnalystConsensusTarget
4.6% infravalorado descuento intrínseco
AnalystConsensusTarget
•2d ago

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

102
0
2
AN
AnalystHighTarget
13.6% infravalorado descuento intrínseco
AnalystHighTarget
•3mo ago

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

30
0
0
AN
AnalystLowTarget
21.9% sobrevalorado descuento intrínseco
AnalystLowTarget
•1mo ago

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

24
0
0
View all narratives

Competidores de Vimian Group AB (publ)

Xvivo Perfusion

Symbol: OM:XVIVO
Market cap: SEK 7.8b

Bio-Works Technologies

Symbol: NGM:BIOWKS
Market cap: SEK 330.0m

MedCap

Symbol: OM:MCAP
Market cap: SEK 7.9b

Attendo

Symbol: OM:ATT
Market cap: SEK 18.1b

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Vimian Group
Precios históricos de las acciones
Precio actual de la acciónSEK 35.45
Máximo en las últimas 52 semanasSEK 36.20
Mínimo de 52 semanasSEK 24.18
Beta1.19
Cambio en 1 mes1.43%
Variación en 3 meses19.76%
Cambio de 1 año16.23%
Variación en 3 años53.20%
Variación en 5 años-62.61%
Variación desde la OPV-56.18%

Noticias y actualizaciones recientes

User avatar
Actualización de narrativa • Sep 14

VIMIAN: Margin Execution And Lower Risk Assumptions Will Shape Balanced Upside Potential

Analysts now cite slightly higher fair value and margin assumptions, along with a modestly lower discount rate, as reasons for raising their SEK 34.98 price target on Vimian Group to SEK 37.17. What’s in the News for Vimian Group No recent company specific news for Vimian Group has been provided in the available sources as of 14 Sep 2026.
Artículo de análisis • Jul 25

Shareholders Can Be Confident That Vimian Group's (STO:VIMIAN) Earnings Are High Quality

Vimian Group AB (publ)'s ( STO:VIMIAN ) strong earnings report was rewarded with a positive stock price move. Our...
User avatar
Actualización de narrativa • Jul 23

VIMIAN: Rich P/E And Slower Revenue Outlook Will Cap Future Upside

Analysts have raised their price target on Vimian Group to SEK29.08 from SEK26.50, citing updated assumptions that include a lower discount rate, slightly lower revenue growth expectations, a higher projected profit margin and a modestly higher future P/E multiple. What’s in the News for Vimian Group Vimian Group AB held its Annual General Meeting on April 29, 2026.
User avatar
Actualización de narrativa • Jun 30

VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside

Analysts have lifted their SEK fair value estimate for Vimian Group from about SEK 24.91 to roughly SEK 26.50. They cited updated assumptions for revenue growth, profit margins and a higher future P/E multiple as key drivers behind the change in price target.

Recent updates

User avatar
Actualización de narrativa • Sep 14

VIMIAN: Margin Execution And Lower Risk Assumptions Will Shape Balanced Upside Potential

Analysts now cite slightly higher fair value and margin assumptions, along with a modestly lower discount rate, as reasons for raising their SEK 34.98 price target on Vimian Group to SEK 37.17. What’s in the News for Vimian Group No recent company specific news for Vimian Group has been provided in the available sources as of 14 Sep 2026.
Artículo de análisis • Jul 25

Shareholders Can Be Confident That Vimian Group's (STO:VIMIAN) Earnings Are High Quality

Vimian Group AB (publ)'s ( STO:VIMIAN ) strong earnings report was rewarded with a positive stock price move. Our...
User avatar
Actualización de narrativa • Jul 23

VIMIAN: Rich P/E And Slower Revenue Outlook Will Cap Future Upside

Analysts have raised their price target on Vimian Group to SEK29.08 from SEK26.50, citing updated assumptions that include a lower discount rate, slightly lower revenue growth expectations, a higher projected profit margin and a modestly higher future P/E multiple. What’s in the News for Vimian Group Vimian Group AB held its Annual General Meeting on April 29, 2026.
User avatar
Actualización de narrativa • Jun 30

VIMIAN: Lower Margin Outlook Will Limit Future Share Price Upside

Analysts have lifted their SEK fair value estimate for Vimian Group from about SEK 24.91 to roughly SEK 26.50. They cited updated assumptions for revenue growth, profit margins and a higher future P/E multiple as key drivers behind the change in price target.
User avatar
Actualización de narrativa • Jun 16

VIMIAN: Lower Discount Rate And New Bylaws Will Support Future Repricing

Analysts have kept their SEK price target for Vimian Group broadly in line with prior estimates, citing slightly adjusted assumptions around the company’s discount rate, revenue growth, profit margin and future P/E as the main drivers of the updated view. What's in the News Vimian Group AB held its Annual General Meeting on April 29, 2026, where shareholders approved the adoption of new Articles of Association.
User avatar
Actualización de narrativa • Jun 01

VIMIAN: New Bylaws And Improved Assumptions Will Support Future Repricing

Analysts now set their fair value price target for Vimian Group at SEK41.03, a slight trim from SEK41.10. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.
User avatar
Actualización de narrativa • May 06

VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential

Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.
User avatar
Actualización de narrativa • Apr 17

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.
User avatar
Actualización de narrativa • Apr 03

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.
User avatar
Actualización de narrativa • Mar 20

VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance

Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.
User avatar
Actualización de narrativa • Mar 05

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
User avatar
Actualización de narrativa • Feb 19

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.
Artículo de análisis • Feb 16

Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Investors in Vimian Group AB (publ) ( STO:VIMIAN ) had a good week, as its shares rose 5.9% to close at kr27.84...
Artículo de análisis • Feb 05

Is Vimian Group (STO:VIMIAN) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Actualización de narrativa • Feb 05

VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade

Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.
User avatar
Actualización de narrativa • Jan 22

VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative

Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.
User avatar
Actualización de narrativa • Jan 08

VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative

Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.
Artículo de análisis • Jan 08

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
User avatar
Actualización de narrativa • Dec 23

VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook

Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.
User avatar
Actualización de narrativa • Dec 09

VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade

Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.
User avatar
Actualización de narrativa • Nov 25

VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience

Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.
Artículo de análisis • Sep 10

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Key Insights The projected fair value for Vimian Group is kr43.69 based on 2 Stage Free Cash Flow to Equity Vimian...
User avatar
Actualización de narrativa • Sep 05

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.
Artículo de análisis • Aug 14

Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

OM:VIMIAN 1 Year Share Price vs Fair Value Explore Vimian Group's Fair Values from the Community and select yours...
Artículo de análisis • Jun 17

If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Artículo de análisis • Jun 02

Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Key Insights Vimian Group's estimated fair value is kr55.41 based on 2 Stage Free Cash Flow to Equity Vimian Group's...
Artículo de análisis • May 15

Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

With a median price-to-sales (or "P/S") ratio of close to 4.6x in the Medical Equipment industry in Sweden, you could...
Artículo de análisis • Mar 05

Is Vimian Group (STO:VIMIAN) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Feb 21

Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

Unsurprisingly, Vimian Group AB (publ)'s ( STO:VIMIAN ) stock price was strong on the back of its healthy earnings...
Artículo de análisis • Feb 14

A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)

Key Insights The projected fair value for Vimian Group is kr54.92 based on 2 Stage Free Cash Flow to Equity Current...
User avatar
Nueva narrativa • Feb 09

iM3 Acquisition Will Expand Presence In Veterinary Dental Space

Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.
Artículo de análisis • Dec 16

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Artículo de análisis • Aug 31

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Vimian Group AB (publ) ( STO:VIMIAN ) shareholders have had their patience rewarded with a 27% share price jump in the...
Artículo de análisis • Aug 17

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Rentabilidad de los accionistas

VIMIANSE Medical EquipmentMercado SE
7D3.7%0.6%-0.7%
1Y16.2%1.4%12.3%

Rentabilidad vs. Industria: VIMIAN superó a la industria Swedish Medical Equipment, que obtuvo un rendimiento del 1.4% el año pasado.

Rentabilidad vs. Mercado: VIMIAN superó al mercado Swedish, que obtuvo un rendimiento del 12.3% el año pasado.

Volatilidad de los precios

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement3.3%
Medical Equipment Industry Average Movement6.3%
Market Average Movement5.2%
10% most volatile stocks in SE Market10.6%
10% least volatile stocks in SE Market2.9%

Precio estable de las acciones: VIMIAN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Swedish.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VIMIAN (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
20201,300Alireza Tajbakhshvimian.com

Vimian Group AB (publ) se dedica al negocio de la salud animal en todo el mundo. Opera a través de los segmentos Specialty Pharma, MedTech, Diagnostics y Veterinary Services. La empresa ofrece diagnósticos patentados y tratamientos con y sin receta para el cuidado preventivo y el tratamiento de enfermedades crónicas de animales de compañía bajo la marca Nextmune; y soluciones moleculares y de inmunodiagnóstico que utilizan los laboratorios para aplicaciones veterinarias específicas centradas en los mercados de la ganadería y la salud de los animales de compañía bajo la marca Indical Bioscience.

Resumen de fundamentos de Vimian Group AB (publ)

¿Cómo se comparan los beneficios e ingresos de Vimian Group con su capitalización de mercado?
Estadísticas fundamentales de VIMIAN
Capitalización bursátilSEK 18.29b
Beneficios(TTM)SEK 415.10m
Ingresos (TTM)SEK 5.09b
45.2x
Ratio precio-beneficio (PE)
3.7x
Ratio precio-ventas (PS)

¿Está VIMIAN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VIMIAN
Ingresos€450.90m
Coste de los ingresos€140.60m
Beneficio bruto€310.30m
Otros gastos€273.50m
Beneficios€36.80m

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Oct 22, 2026

Beneficios por acción (BPA)0.07
Margen bruto68.82%
Margen de beneficio neto8.16%
Ratio deuda/patrimonio35.1%

¿Cómo se ha desempeñado VIMIAN a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/09/17 17:52
Precio de las acciones al final del día2026/09/17 00:00
Beneficios2026/06/30
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
  • Formulario SEC 10-K
  • Formulario SEC 10-Q
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
  • Informes de análisis
  • Blue Matrix
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
  • Datos de mercado ICE
  • Formulario S-1 de la SEC
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
  • Formulario SEC 4
  • Formulario SEC 13D
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
  • Formulario SEC 10-K
  • Formulario SEC DEF 14A
Principales avances10 años
  • Anuncios de empresas
  • Formulario SEC 8-K

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Vimian Group AB (publ) está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
null nullABG Sundal Collier
Jonathon UnwinBarclays
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB

Toma mejores decisiones de inversión en cualquier lugar

Escanea para descargar
Abrir AppStoreAbrir Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Ver fuentes de datos
Mercados
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Ideas de inversión
  • Empresas infravaloradas
  • Potentes generadores de dividendos
  • Compras con información privilegiada
  • Energía nuclear
  • Vehículos autónomos
  • Inteligencia artificial
  • Criptomonedas y blockchain
  • Ciberseguridad
  • Más ideas
Comunidades de acciones
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Herramientas y funciones
  • Seguimiento de la cartera
  • Buscador de valores y alertas
  • Narrativas y Valores de Feria
  • Calculadora de dividendos
Noticias y descubrimientos
  • Últimas noticias de stock
  • Incidencias del mercado global
  • El Foxhole
  • Ideas de inversión
  • Narrativas de la comunidad
  • Qué hay de nuevo
Simply Wall St
  • Planes y precios
  • Publicidad
  • Quiénes somos
  • Contacte con nosotros
  • Empleos
  • Centro de ayuda
  • Aprender a invertir en bolsa
  • Programa de afiliados
  • Empresas y negocios
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Términos y condiciones de uso
  • Política de privacidad
  • Términos de IA
  • Guía de servicios financieros